| Code | CSB-RA025141MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to APG333, targeting thymic stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine that plays a critical role in initiating and amplifying type 2 inflammatory responses. TSLP is primarily produced by epithelial cells in the skin, lungs, and gastrointestinal tract in response to tissue damage, allergens, and inflammatory stimuli. By activating dendritic cells and promoting Th2 cell differentiation, TSLP contributes to the pathogenesis of multiple allergic and inflammatory conditions, including atopic dermatitis, asthma, chronic obstructive pulmonary disease, and eosinophilic esophagitis.
APG333 is a therapeutic monoclonal antibody developed to neutralize human TSLP, preventing its interaction with the TSLP receptor complex. This biosimilar antibody serves as a valuable research tool for investigating TSLP-mediated signaling pathways, exploring the cytokine's role in allergic inflammation, and studying potential therapeutic interventions for type 2 immune-mediated diseases. It enables researchers to examine TSLP blockade effects in various experimental models and cellular assays.
There are currently no reviews for this product.